Ozempic Economics: Your Questions Answered
GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound have been revolutionary for weight loss. They\u2019re also sparking big changes in many industries \u2013 from food to medicine. Wall Street Journal tech editor Bradley Olson \u2013 who himself took a GLP-1 drug \u2013 and audio reporter Jessica Mendoza have been documenting impacts of this new class of drugs in a series \u2013 \u201cTrillion Dollar Shot\u201d \u2013 for our sister podcast The Journal. They answer listener questions on how it\u2019s transforming bodies, fortunes and industries. Luke Vargas hosts.\n\n\n\nFurther Reading\n\nThe Quest for Treatments to Keep Weight Off After Ozempic\xa0\n\nCan Ozempic Maker Novo Nordisk Keep Up Its Momentum?\xa0\n\nHow Drugs Like Ozempic Are Changing What We Think About Weight Loss\xa0\n\nLearn more about your ad choices. Visit megaphone.fm/adchoices